IHS Chemical Week

Regions :: North America :: U.S.

Lonza and Sorrento Therapeutics sign research license agreement

9:28 AM MDT | August 7, 2013 | Deepti Ramesh

Lonza and Sorrento Therapeutics (San Diego), a publicly traded, development-stage biopharmaceutical company, say that they have signed a nonexclusive research license agreement for access to Lonza’s GS Xceed Gene Expression System.  The GS Xceed System will be used in the generation of stable expression cell lines for the production and development of therapeutic antibodies in Sorrento’s product portfolio. The research license agreement will give Sorrento access to Lonza’s GS technology for use in Sorrento’s maturing pipeline of...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa